Learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.
Jason Schafer, PharmD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 1.05 MB
Released: March 15, 2022
Acknowledgements
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
